ArticleFrontiers in immunology2026
Complete response in metastatic clear cell renal cell carcinoma following pembrolizumab-axitinib and subsequent nephrectomy: a Case Report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal cell carcinoma (RCC) is the most common kidney cancer in adults. The advent of immune checkpoint inhibitors (ICIs), particularly in combination with tyrosine kinase inhibitors (TKIs), has significantly improved outcomes in advanced disease. Case presentation: A 67-year-old woman with stage IV clear cell RCC and intermediate-risk features presented with pulmonary, nodal, and peritoneal metastases. She received first-line pembrolizumab plus axitinib, achieving durable disease control and partial response with good tolerability. After 32 months she achieved sustained disease stability and underwent robot-assisted left nephrectomy. Histology revealed complete pathological response. Postoperatively, pembrolizumab was continued with a pseudo-adjuvant intent, and as of March 2026, the patient remains in radiological near-complete response with a progression-free survival of approximately 41 months from treatment initiation. Discussion and conclusions: This case illustrates that ICI-TKI combinations can induce profound and durable responses even in intermediate-risk metastatic RCC. Consolidative surgery after systemic control, though still under debate, may be beneficial for carefully selected patients. Overall, this report underscores the potential of immunotherapy-TKI combinations to achieve long-term remission and the importance of a multidisciplinary, personalized treatment approach in advanced RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.